.png)
Trend Report
mRNA: The State of Play in Oncology and Infectious Disease
A data-driven analysis of where mRNA innovation is headed in oncology and infectious disease — and the primary packaging considerations that will determine whether the next generation of therapies reaches patients safely.
Status
Published
Format
Trend Report
Language
English
Access
Registration Required
Resource Overview
About this Trend Report
Building on the landmark success of COVID-19 mRNA vaccines Comirnaty and Spikevax, the pharmaceutical industry is now advancing mRNA technology into a broad range of disease areas — with 1,035 drug candidates in the pipeline as of early 2024, spanning infectious disease, oncology, genetic disorders, metabolic conditions, and central nervous system indications.
This 2024 report by Datwyler draws on GlobalData's proprietary pipeline analytics to assess the state of mRNA innovation across both infectious disease (45% of active pipeline) and oncology (27%), analyzing clinical trial trends, late-stage candidates, and the competitive landscape of companies including Moderna, BioNTech, and CureVac. On the packaging side, the report addresses the significant primary packaging challenges posed by mRNA's ultra-cold storage requirements — including the impact of deep-freeze and freeze-thaw cycles on elastomeric component performance, container closure integrity (CCI), and glide force. It details Datwyler's validated testing of plunger performance at -50°C, the rationale for uncoated versus coated rubber components in vials and prefilled syringes at ultra-low temperatures. Datwyler's recognition by BioNTech as a pivotal partner in COVID-19 vaccine supply underscores its established role in supporting mRNA drug manufacturers at scale.
Access This Resource
Download the Trend Report
Continue to access the full resource.
Read the Report
Quick access in under 30 seconds.
Expert Spotlight
Meet the Expert
Geert Moens
Global Platform Leader, Vial Closure Systems
·
Datwyler
Geert Moens holds a university degree in Public Administration. After working in the Human Resources domain, he joined Datwyler in 2007. Geert has over a decade of experience within Datwyler as a Key Account Manager being responsible for various strategic pharmaceutical accounts throughout Europe and beyond. In this role he has developed a thorough insight in the landscape of pharmaceutical parenteral packaging components. In 2018, Geert became the strategic lead of Datwyler’s vial closure system components as a Global Platform Leader, where he drives the product and service portfolio, product and service innovations and formulates the market approach.